SHANGHAI – Newcomer Ark Biosciences Inc., of Shanghai, has announced its first deal with the acquisition of global rights to Roche AG's respiratory syncytial virus (RSV) drug candidate, AK0529. RSV is one of the most infectious human viruses and the number one cause of death and hospitalization for children younger than 5. There is currently no vaccine or therapeutic drug for RSV infection.